Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial
Abstract Background The primary aim of this trial was to determine the recommended phase II dose (RP2D) of weekly paclitaxel (wP) administered in combination with oral metronomic cyclophosphamide (OMC). Methods Patients ≥ 18 years of age with refractory metastatic cancers were eligible if no standar...
Main Authors: | Diane Pannier, Antoine Adenis, Emilie Bogart, Eric Dansin, Stéphanie Clisant-Delaine, Emilie Decoupigny, Anne Lesoin, Eric Amela, Sandrine Ducornet, Jean-Pierre Meurant, Marie-Cécile Le Deley, Nicolas Penel |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-07-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-4678-x |
Similar Items
-
Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study
by: Roze Isono-Taniguchi, et al.
Published: (2022-08-01) -
Effectiveness and toxicity of metronomic oral cyclophosphamide for recurrent or platinum-refractory ovarian cancer: A meta-analysis
by: Lili Huang, et al.
Published: (2022-08-01) -
Oral etoposide and cyclophosphamide: A low-cost palliative metronomic chemotherapy in advanced pediatric cancers
by: Kiran Kumar, et al.
Published: (2020-01-01) -
Metronomic Chemotherapy for Palliative Treatment of Malignant Oral Tumors in Dogs
by: Nina Milevoj, et al.
Published: (2022-03-01) -
Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer
by: Vanita Noronha, et al.
Published: (2016-01-01)